FDA Approves First mRNA-Based Influenza Vaccine From Moderna for Adults Aged 50 and Older

The FDA has approved Moderna's mFLUSIVA, the first mRNA-based vaccine for seasonal flu, for adults 50 and older, marking a significant advancement in mRNA technology.